Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officer.

On June 30, 2020, Minerva Neurosciences, Inc. (the "Company") notified its President, Rick Russell, that it terminated his employment without cause, effective as of June 30, 2020. Such decision was the result of the Company's alignment of human and financial resources with its focus on establishing a path to approval of its lead compound, roluperidone. As contemplated by Mr. Russell's offer letter dated October 31, 2017, which was filed with the Securities and Exchange Commission as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on December 11, 2017, Mr. Russell is entitled to receive a severance payment equal to continued payment of 12 months of his annualized base salary at the time of termination, payment of the pro-rata portion of his annual bonus for 2020 and immediate vesting of any unvested options, restricted stock, restricted stock units and other equity awards granted to Mr. Russell and outstanding immediately prior to the date of termination that would have vested during the 12-month period immediately following the termination date.

© Edgar Online, source Glimpses